News >

Trastuzumab-Associated Cardiac Events Reversible, Outweighed by Benefits

Christina Izzo
Published: Monday, Jul 14, 2014

Dr.Edward H. Romond

Edward H. Romond, MD

Cardiac events associated with trastuzumab (Herceptin) are mostly reversible and outweighed by significant extensions in overall survival (OS) and progression-free survival (PFS) for patients with HER2-positive breast cancer, according to analyses from several clinical trials exploring the drug.

  1. de Azambuja E, Procter MJ, van Veldhuisen DJ, et al. Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01). J Clin Oncol. 2014;32(20):2159-2165.
  2. Balduzzi S, Mantarro S, Guarneri V, et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews 2014, Issue 6. Art. No.: CD006242. DOI: 10.1002/14651858.CD006242.pub2.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication